INS and Alzheimer disease: In 2017, a longer pilot clinical trial comparing regular insulin to insulin detemir was conducted, where 36 adults diagnosed with MCI or AD were randomly assigned to placebo (n = 12), 40 IU of regular insulin (n = 12), or 40 IU of insulin detemir (n = 12) daily, over a 4-month period [81].